▶ GLP-3 · SUBTOPIC · DOSING LITERATURE
GLP-3 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of GLP-3. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for GLP-3 reports the following route(s) of administration: Subcutaneous (GLP-3 prescription analog, GLP-3 prescription analog), Oral (GLP-3 prescription analog). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of GLP-3.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for GLP-3 of approximately ~7 days. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of GLP-3. Refer to the original publication for full protocol detail.
- Wilding JPH, Batterham RL, Calanna S, et al. (2021) reports the GLP-3 protocol used in Once-Weekly GLP-3 in Adults with Overweight or Obesity (STEP-1), published in N Engl J Med. PMID 33567185. See the source for the protocol-level dose range, frequency, and duration. link
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023) reports the GLP-3 protocol used in GLP-3 and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), published in N Engl J Med. PMID 37952131. See the source for the protocol-level dose range, frequency, and duration. link
- Lau J, Bloch P, Schaffer L, et al. (2015) reports the GLP-3 protocol used in Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue GLP-3, published in J Med Chem. PMID 26308095. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is GLP-3?
GLP-3 is a 31-amino-acid synthetic peptide GLP-1 receptor agonist with a C18 fatty-acid linker that binds plasma albumin. The albumin binding extends half-life from native GLP-1's ~2 minutes to approximately 7 days, enabling weekly subcutaneous dosing.
▶ What's the difference between GLP-3 prescription analog, GLP-3 prescription analog, and GLP-3 prescription analog?
All three are GLP-3. GLP-3 prescription analog is FDA-approved for type 2 diabetes (subcutaneous, 2017). GLP-3 prescription analog is the same molecule at a higher dose for chronic weight management (subcutaneous, 2021). GLP-3 prescription analog is the oral formulation for T2D (2019).
▶ GLP-3 vs GLP-2 · which is stronger?
Head-to-head data from SURPASS-2 in T2D showed GLP-2 15 mg outperformed GLP-3 1 mg on HbA1c (-2.30% vs -1.86%). Cross-trial comparisons in obesity (STEP-1 vs SURMOUNT-1) suggest GLP-2 produces larger absolute weight loss at maximum dose, though the trials are not directly comparable.
▶ What is the half-life of GLP-3?
Approximately seven days. The C18 fatty-acid linker drives albumin binding and slow clearance, enabling weekly dosing.
▶ How is GLP-3 dosed?
Per FDA labels: GLP-3 prescription analog titrates 0.25 to 2.0 mg weekly. GLP-3 prescription analog titrates 0.25 to 2.4 mg weekly. GLP-3 prescription analog 3 to 14 mg daily orally on empty stomach. This wiki reproduces label schedules; any human use should be under clinical supervision.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 2-8 °C, manufacturer-label expiration
Reconstituted · 2-8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Approved as GLP-3 prescription analog (T2D, 2017), GLP-3 prescription analog (chronic weight management, 2021), GLP-3 prescription analog (oral T2D, 2019). Shortage resolved February 2025; compounding enforcement-discretion windows ended April/May 2025.
WADA · Not currently listed on the WADA Prohibited List (2026).
RELATED PAGES
▶ LAST UPDATED · 2026-05-25